CVApr 6, 2022

Instance Segmentation of Unlabeled Modalities via Cyclic Segmentation GAN

Harvard
arXiv:2204.03082v15 citationsh-index: 91
Originality Incremental advance
AI Analysis

This addresses the problem of expensive annotation for new imaging modalities in biomedical research, offering an incremental improvement over existing methods.

The paper tackles instance segmentation for unlabeled imaging modalities by proposing CySGAN, a unified framework that jointly performs image translation and segmentation, outperforming pretrained models and sequential baselines on 3D neuronal nuclei segmentation with EM and ExM data.

Instance segmentation for unlabeled imaging modalities is a challenging but essential task as collecting expert annotation can be expensive and time-consuming. Existing works segment a new modality by either deploying a pre-trained model optimized on diverse training data or conducting domain translation and image segmentation as two independent steps. In this work, we propose a novel Cyclic Segmentation Generative Adversarial Network (CySGAN) that conducts image translation and instance segmentation jointly using a unified framework. Besides the CycleGAN losses for image translation and supervised losses for the annotated source domain, we introduce additional self-supervised and segmentation-based adversarial objectives to improve the model performance by leveraging unlabeled target domain images. We benchmark our approach on the task of 3D neuronal nuclei segmentation with annotated electron microscopy (EM) images and unlabeled expansion microscopy (ExM) data. Our CySGAN outperforms both pretrained generalist models and the baselines that sequentially conduct image translation and segmentation. Our implementation and the newly collected, densely annotated ExM nuclei dataset, named NucExM, are available at https://connectomics-bazaar.github.io/proj/CySGAN/index.html.

Foundations

The foundational work for this paper's niche, ranked by how specifically the neighbourhood builds on it — not by global fame.

Your Notes